CVRX — CVRx, Inc.

CVRx Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $16 million, up 4% year-over-year.
• Full Year Revenue: $56.7 million, up 10% year-over-year.
• U.S. Revenue: $14.9 million for Q4, also a 4% increase.
• Gross Profit: $13.8 million for Q4, an 8% increase, with gross margin improving to 86% from 83%.
• Net Loss: $11.9 million, or $0.46 per share, compared to a net loss of $10.7 million, or $0.43 per share, in Q4 2024.
• Cash Position: $75.7 million at year-end, with an additional $10 million borrowed in January 2026, bringing total available cash to $86 million.

2. Strategic Updates and Business Highlights

• Sales Organization Transformation: Expanded to 53 territories and 252 active implanting centers, with a focus on building a world-class sales team and driving deep adoption in targeted centers.
• Barostim Therapy: Positioned as a critical treatment for heart failure, addressing quality of life issues for patients.
• Category 1 CPT Codes: Transition effective January 1, 2026, expected to improve patient access and reimbursement predictability.
• BENEFIT-HF Trial: Landmark trial initiated to evaluate Barostim's impact on heart failure outcomes, potentially expanding the addressable market from 339,000 to over 980,000 patients, effectively tripling the market opportunity.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $63 million and $67 million, reflecting an 11% to 18% growth rate.
• Gross Margin Guidance: Anticipated between 84% and 86%.
• Operating Expenses: Expected to be between $103 million and $107 million for the full year.
• Q1 2026 Revenue Guidance: Projected between $13.7 million and $14.7 million, with a seasonal dip expected from Q4 to Q1.

4. Bad News, Challenges, or Points of Concern

• Net Loss Increase: The net loss widened compared to the previous year, indicating ongoing financial challenges.
• Sales Growth Impact: The integration of new sales representatives has created short-term impacts on growth, although long-term confidence remains.
• Market Penetration: Despite a significant market opportunity, Barostim therapy penetration remains below 1%, indicating challenges in scaling adoption.
• Trial Costs: The BENEFIT-HF trial is expected to incur net cash impacts of $20 million to $30 million over 5 to 7 years, which may affect short-term profitability.

5. Notable Q&A Insights

• BENEFIT-HF Trial Revenue Impact: While the trial is not expected to significantly contribute to immediate revenue, it is anticipated to enhance goodwill and credibility within the heart failure community.
• Sales Strategy: The focus is on deeper adoption at existing centers rather than just adding new accounts, with expectations of high single-digit account growth in 2026.
• Sales Rep Productivity: Progress is being made in getting sales representatives up the productivity curve, with expectations for continued improvement throughout 2026.
• Path to Profitability: Management emphasized leveraging the sales force's productivity to drive revenue growth faster than operating expense increases, with sufficient cash reserves to sustain operations through the transition period.

This summary captures the essential elements of CVRx's Q4 2025 earnings call, highlighting financial performance, strategic initiatives, future outlook, and key concerns.